Race Oncology (ASX:RAC) has announced that the investigator-sponsored Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine in relapsed or refractory acute myeloid leukaemia patients has been successfully concluded having achieved its primary endpoint for efficacy. …
Race Oncology says Phase 2 trial of Bisantrene meets predetermined efficacy criteria
July 30, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Amplia announces capital raise to support the completion of Phase 2a ACCENT tr
October 30, 2024 - - Australian Biotech -
Priceline Pharmacy launches a refreshed brand strategy
October 30, 2024 - - Latest News -
Vaccine procurement and rollout was slow, but reduced the number of deaths
October 30, 2024 - - Latest News -
Boehringer Ingelheim leader promoted to global role
October 30, 2024 - - Latest News -
At least this means the industry will never again take lectures on these issues
October 29, 2024 - - Latest News -
Decisions taken during the caretaker period are governed by a formal convention
October 29, 2024 - - Latest News -
Community pharmacy leads nationwide transformation of women’s health services
October 29, 2024 - - Latest News